Corrigendum to Wick et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016 Jul 1. pii: now133 first published online July 1, 2016 doi:10.1093/neuonc/now133.
The authors of this article wish to declare that a co-author’s name was omitted. The omitted author’s name is Torsten Pietsch, who is affiliated with the Department of Neuropathology at the University of Bonn and belongs to the NOA Working Group of the German Cancer Society. The position of the author’s name is given below:
Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Pietsch T, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M; Neurooncology Working Group (NOA) of the German Cancer Society.